Addex Therapeutics Stock Piotroski F Score

ADXN Stock  USD 7.20  0.77  9.66%   
This module uses fundamental data of Addex Therapeutics to approximate its Piotroski F score. Addex Therapeutics F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Addex Therapeutics. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Addex Therapeutics financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Addex Therapeutics Altman Z Score, Addex Therapeutics Correlation, Addex Therapeutics Valuation, as well as analyze Addex Therapeutics Alpha and Beta and Addex Therapeutics Hype Analysis.
To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.
  
At this time, Addex Therapeutics' Short and Long Term Debt Total is very stable compared to the past year. As of the 4th of December 2024, Long Term Debt Total is likely to grow to about 214 K, while Net Debt is likely to drop (3.7 M). At this time, Addex Therapeutics' EV To Free Cash Flow is very stable compared to the past year.
At this time, it appears that Addex Therapeutics' Piotroski F Score is Poor. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
4.0
Piotroski F Score - Poor
Current Return On Assets

Negative

Focus
Change in Return on Assets

Increased

Focus
Cash Flow Return on Assets

Negative

Focus
Current Quality of Earnings (accrual)

Improving

Focus
Asset Turnover Growth

Increase

Focus
Current Ratio Change

Decrease

Focus
Long Term Debt Over Assets Change

N/A

Focus
Change In Outstending Shares

Increase

Focus
Change in Gross Margin

No Change

Focus

Addex Therapeutics Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Addex Therapeutics is to make sure Addex is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Addex Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Addex Therapeutics' financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.360.3475
Sufficiently Up
Slightly volatile
Total Current LiabilitiesM2.9 M
Significantly Up
Pretty Stable
Non Current Liabilities Total761.6 K603.1 K
Significantly Up
Slightly volatile
Total Assets4.4 M4.6 M
Notably Down
Slightly volatile
Total Current AssetsM4.2 M
Notably Down
Slightly volatile

Addex Therapeutics F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Addex Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Addex Therapeutics in a much-optimized way.

About Addex Therapeutics Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Book Value Per Share

0.0146

At this time, Addex Therapeutics' Book Value Per Share is very stable compared to the past year.

Addex Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Addex Therapeutics from analyzing Addex Therapeutics' financial statements. These drivers represent accounts that assess Addex Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Addex Therapeutics' important valuation drivers and their relationship over time.
201920202021202220232024 (projected)
Market Cap43.3M53.1M35.5M4.5M3.4M3.2M
Enterprise Value12.3M35.0M15.5M(2.0M)(103.0K)(97.8K)

Addex Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Addex Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Addex Therapeutics' managers, analysts, and investors.
Environmental
Governance
Social

About Addex Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Addex Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Addex Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Addex Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Pair Trading with Addex Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Addex Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Addex Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Addex Stock

  0.74VALN Valneva SE ADRPairCorr

Moving against Addex Stock

  0.69VCYT VeracytePairCorr
  0.63VCEL Vericel Corp OrdPairCorr
  0.53VERA Vera TherapeuticsPairCorr
  0.43DRTS Alpha Tau MedicalPairCorr
  0.42VANI Vivani MedicalPairCorr
The ability to find closely correlated positions to Addex Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Addex Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Addex Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Addex Therapeutics to buy it.
The correlation of Addex Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Addex Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Addex Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Addex Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Addex Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Addex Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Addex Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Addex Therapeutics Stock:
Check out Addex Therapeutics Altman Z Score, Addex Therapeutics Correlation, Addex Therapeutics Valuation, as well as analyze Addex Therapeutics Alpha and Beta and Addex Therapeutics Hype Analysis.
To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.
You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Addex Therapeutics. If investors know Addex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Addex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(21.76)
Revenue Per Share
1.2
Quarterly Revenue Growth
(0.82)
Return On Assets
(0.62)
Return On Equity
(1.26)
The market value of Addex Therapeutics is measured differently than its book value, which is the value of Addex that is recorded on the company's balance sheet. Investors also form their own opinion of Addex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Addex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Addex Therapeutics' market value can be influenced by many factors that don't directly affect Addex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Addex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Addex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Addex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.